header logo image


Page 48«..1020..47484950..60..»

Archive for the ‘Regenerative Medicine’ Category

William Prather of Pluristem on treating Aplastic Anemia with stem cells – at Stem Cells USA 2012 – Video

Saturday, December 22nd, 2012


William Prather of Pluristem on treating Aplastic Anemia with stem cells - at Stem Cells USA 2012
William Prather, Sr. VP Corporate Development at Pluristem, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Treating Aplastic Anemia with PLX Stem Cells. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:02More inScience Technology

Continued here:
William Prather of Pluristem on treating Aplastic Anemia with stem cells - at Stem Cells USA 2012 - Video

Read More...

Edward Lanphier of Sangamo on engineering genetic cures – at Stem Cells USA

Saturday, December 22nd, 2012


Edward Lanphier of Sangamo on engineering genetic cures - at Stem Cells USA RM Congress 2012
Edward Lanphier, CEO of Sangamo, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Engineering genetic cures: employing zinc finger nucleases (ZFNs) in stem cells. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:24:15More inScience Technology

Read the original post:
Edward Lanphier of Sangamo on engineering genetic cures - at Stem Cells USA

Read More...

Michael West of BioTime on hES cell-based therapies – at Stem Cells USA

Saturday, December 22nd, 2012


Michael West of BioTime on hES cell-based therapies - at Stem Cells USA RM Congress 2012
Michael West, CEO of BioTime, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Second generation hES cell-based therapies: achieving purity and scalability in the midst of diversity. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:23:31More inScience Technology

Here is the original post:
Michael West of BioTime on hES cell-based therapies - at Stem Cells USA

Read More...

Teresa Leezer of Rhinocyte on neurodegenerative conditions – at Stem Cells USA

Saturday, December 22nd, 2012


Teresa Leezer of Rhinocyte on neurodegenerative conditions - at Stem Cells USA RM Congress 2012
Teresa Leezer, COO of Rhinocyte, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Using autologous olfactory epithelial cells to treat neurodegenerative conditions. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:14:58More inScience Technology

The rest is here:
Teresa Leezer of Rhinocyte on neurodegenerative conditions - at Stem Cells USA

Read More...

Ed Field of Cytomedix on biotech collaboration in RM – at Stem Cells USA

Saturday, December 22nd, 2012


Ed Field of Cytomedix on biotech collaboration in RM - at Stem Cells USA RM Congress 2012
Ed Field, Chief Operating Officer of Cytomedix, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Biotech collaboration in RM: Cytomedix #39;s acquisition of Aldagen. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:24:03More inScience Technology

Original post:
Ed Field of Cytomedix on biotech collaboration in RM - at Stem Cells USA

Read More...

Alternative funding sources for regenerative medicine – panel discussion at Stem Cells USA 2012 – Video

Saturday, December 22nd, 2012


Alternative funding sources for regenerative medicine - panel discussion at Stem Cells USA 2012
Stem Cells USA Regenerative Medicine Congress 2012 featured an exciting panel discussion on the topic, #39;Looking to alternative funding sources for the regenerative medicine field. #39; Panelists included: Ed Field, Chief Operating Officer, Cytomedix Dan Gincel, Director, Maryland Stem Cell Research Fund Elona Baum, General Counsel, California Institute for Regenerative Medicine (CIRM) Brock Reeve, Executive Director, Harvard Stem Cell Institute The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:50:04More inScience Technology

Visit link:
Alternative funding sources for regenerative medicine - panel discussion at Stem Cells USA 2012 - Video

Read More...

Mathew Vincent of ACT on hESC derived RPE cells – at Stem Cells USA

Saturday, December 22nd, 2012


Mathew Vincent of ACT on hESC derived RPE cells - at Stem Cells USA RM Congress 2012
Mathew Vincent, Director of Business Development at Advanced Cell Technology, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Meaningful clinical results with hESC derived RPE cells in patients with SMD and Dry AMD. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 1ratingsTime:25:03More inScience Technology

See the original post here:
Mathew Vincent of ACT on hESC derived RPE cells - at Stem Cells USA

Read More...

Robert Hariri of Lifebank USA on cord blood and RM space – at World Cord Blood Congress 2012 – Video

Thursday, December 20th, 2012


Robert Hariri of Lifebank USA on cord blood and RM space - at World Cord Blood Congress 2012
Dr. Robert Hariri, President of Lifebank USA spoke at the World Cord Blood Congress 2012 on the topic, #39;Increasing cord blood presence in the regenerative medicine space. #39; World Cord Blood Congress is where private and public cord blood banks, pharma and biotechs, academia and government come to debate advances in cord blood banking and therapeutics. For more information, go to http://www.terrapinn.com/cordblood. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:24:11More inScience Technology

Here is the original post:
Robert Hariri of Lifebank USA on cord blood and RM space - at World Cord Blood Congress 2012 - Video

Read More...

Dean Tozer of Shire Regenerative Medicine – at Stem Cells USA

Thursday, December 20th, 2012


Dean Tozer of Shire Regenerative Medicine - at Stem Cells USA Regenerative Medicine Congress 2012
Dean Tozer, Senior Vice President of Corporate Development at Shire Regenerative Medicine, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Going all-in: Shire #39;s $750M bet on Shire Regenerative Medicine. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:18:23More inScience Technology

Here is the original post:
Dean Tozer of Shire Regenerative Medicine - at Stem Cells USA

Read More...

PhD training programme – Video

Wednesday, December 19th, 2012


PhD training programme
Stem cells regenerative medicine is an exciting and fast moving field that brings together experts in biology, medicine, chemistry, engineering and other areas to find solutions to some of the most challenging scientific and medical problems we face today. The MRC Centre for Regenerative Medicine at the University of Edinburgh offers an integrated and structured PhD training programme in stem cells and regenerative medicine, incorporating taught and research elements to provide high-level training in theoretical and practical stem cell research. More info: http://www.crm.ed.ac.ukFrom:CRMedinburghViews:5 0ratingsTime:01:56More inPeople Blogs

See the original post here:
PhD training programme - Video

Read More...

A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments

Sunday, December 16th, 2012
Tweet 


Further to my recent post, "Six steps to fighting non-compliant cell therapy treatments. The stuff of grey shades, spades, ivory towers and (ahem) balls.", I have crafted a 6-point platform that I propose to submit (with potential edits based on preliminary feedback) to several of the leading  industry and professional organizations for their consideration including ARM, ISCT, ISSCR, FACTAABB  ICMS, and perhaps, in due course, to patient groups, physician groups, disease-specific professional organizations (e.g, cardiology, oncology, neurology, cosmetic, etc).



I welcome comments and feedback. 


1. In addition to helping patients distinguish between compliant and non-compliant treatments (and providers) we must do more to help patients distinguish between non-compliant cell therapy treatments (and providers) which are more or less risky. 


2. Whatever we do in response to this issue should be done with an eye to being practical and helpful to patients in the real-life context of their decision about whether or not to buy a non-complaint cell therapy.


3. Our response to this issue should be based on a risk-based approach recognizing that not all non-compliance is created equal.  We should create a framework for risk-based analysis (both for us and our audiences) and focus initiatives around those which present the highest risk.


4. We recognize the problem of non-compliant cell therapies is not just a problem that exists in jurisdictions with little, no, or poor regulation but that is a growing problem even in the most highly regulated jurisdictions meaning the solution cannot be regulated it depends on education and enforcement.


5. We recognize regulatory agencies cannot enforce non-compliance on their own.  We as an industry need to complement their efforts through our own standards and enforcement.


6. Stakeholder groups should support the formation of a multi-organizational  initiative to, based on a risk-based assessment, spotlight the categories or signs of highest-risk offenders for use by patients and/or their physicians in identifying  whether or not treatments (and providers) they may be considering fall into the that category associated with the highest level of risk.


What do you think?

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/wkSMxAV9938/a-proposed-6-step-platform-for-cell.html

Read More...

The ROI on pant-wearing and other social media tips

Sunday, December 16th, 2012
Tweet 

With many things in life, there is a payoff for doing them.  Do the dishes and the kitchen is cleaner, your household is more functional, and hopefully one or more family members notice and appreciate you for it.



For other things, however,  the people around you have such high expectations you'll do them that you only lose points if you don't but gain very little if you do.  For you, this may be true of the dishes.  Certainly I've always maintained this is true for Valentine's Day.  Get flowers and you simply maintain the relationship's status quo; fail to do anything and you lose big points fast.  


Similarly, at some point certain things become so ubiquitous that they are expected as a baseline.  This is true of putting on your pants.

The global head of social media for Ford Motor Company, Scott Monty, once asked, "What's the ROI* of putting your pants on in the morning?".   The truth is that there is very little benefit to putting on your pants other than to avoid the significant cost of not doing so.

Certainly this is true now of having a website or an email address for your company.  Unlike a couple decades ago, no company gets kudos for having a website or email addresses but it would certainly raise eyebrows of criticism if your company failed to have them.

Arguably social media participation is not quite there yet but it is, I submit, fast approaching.  Someday in the not-too-distant future you will receive the cringe of shame if your company is not active in the leading social media platforms of the day.  Today - for companies - these are LinkedIn, Twitter, and Facebook.  This will be true irrespective of whether yours is a B2B or B2C company.
Recently I was invited to write an article for Future Medicine's special issue for the World Stem Cell Report.  I was asked to make the case for why and how participating in social media stood to benefit the scientists, companies, executives, employees, academics, activists, and other stakeholders in the cell therapy industry.  

The result is "Why the stem cell sector must engage with social media".  What I attempted to succinctly outline are the ways social media primarily benefit one's career and organization or company.


"I can tell you without the slightest hesitation of conviction – having experienced it myself and seen it repeated countless times – is that active and successful social media engagement translates into:

  • Unparalleled learning: accessing more information relevant to your discipline, specialty and company than you otherwise will. 
  • Enhanced profile: higher profile within your industry, profession, specialty and community. Social media is not the only way to build a profile but it can be very effective.
  • Wider network: more touch points and meaningful relationships with people than you otherwise will accomplish by any other means combined."
The measurable impacts and benefits are real and certainly include:
  • Traffic: "For companies, increased traffic equals increased opportunity to call readers/viewers to your intended action – interaction, citation, linking, investing, buying or engaging in some other action you solicit. For individual professionals, increased viewers translate into more chances for collaboration, citation, engagement, etc."
  • Collaboration: "There is an intrinsic correlation between one’s profile and the opportunities one has for collaboration. For companies this means finding the right partnerships, joint ventures, strategic alliances, collaborators, employees, management and so on. For individual professionals, this means more and/or better quality invites to speak, write or collaborate in other ways. It also means finding quality grad students, faculty, employees and interns
  • Revenue/IncomeThis is about translating a broader knowledge base and a wider network over which you have some level of influence (if only just that they are listening) into more money for your company, organization and yourself. For companies, this means finding the right partners, investors, customers and so on. For organizations this means finding the right donors, impressing the right grant reviewers and/or recruiting the right rain-maker faculty. For individual professionals this translates into promotions or job offers."

As I conclude my article I will conclude here:

    "In order to create the kinds of perceptions and solicit the kinds of actions we want from the world around us, we must engage the world around us. The world around us is engaging online. 

    For all kinds of selfish and selfless reasons you, your company or organization and your career will benefit from you engaging there too."

    and this prediction:

    "...in less than the blink it took for the commercial world to accept websites and email, it will seem similarly ridiculous for professionals, academics and companies to operate and succeed without actively using social media."

    ____________


    If this topic is of interest to you, here are some great resources particularly focused on the value of social media to those in life sciences.


    Canaday, M. Is Life Science Social Media Worth It Yet? Three Tenets Behind Its Relevance To Your Business. Comprendia. 6 December 2012. 


    Bersenev A. Scientific blogging as a model for professional networking online. Cellular Therapy and Transplantation. 2010;2(7). 10.3205/ctt-2010-en-000084.01. 


    Bersenev, A. Scientific blogging as a model for professional networking online. 4 August 2010. StemCellAssays.com 


    Bersenev, A. Who’s Who in the Stem Cell Blogosophere.  27 June 2011. StemCellAssays.com 


    Bishop, D.  How to bury your academic writing. Bishop’s Blog. 26 August 2012. 



    Buckler, L. If You’re Breathing, You’re in PR. Cell Therapy Blog. 11 June 2010.  

    Buckler, L. Don’t feel the pain of ignoring social media? Just wait a minute…. CellTherapyBlog.com 22 October 2008.    

    Jewell, T. Survey: How our scientists use social media. AZHealthConnections.com. 12 February 2012. 


    Knoepfer, P. Top ten tips for blogging for scientists. 2 August 2012. IPScell.com   


    Shipman, M. Why Scientists Should Publicize Their Findings – for Purely Selfish Reasons. Scientific America. Blog. 18 June 2012. 
         
    Shipman, M. A gentle introduction to Twitter for the apprehensive academic. Scientific America. Blog.  14 June 2011.  


    Small, G. Time to Tweet. Nature 2011. 479 141 2 November 2011 


    Wilcox, C. Social Media for Scientists Part 1: It’s Our Job. Scientific American Blog. 27 September 2011.  


    Wilcox, C. Social Media for Scientists Part 2: You Do Have time. Scientific American Blog. 29 September 2011.  


    Wilcox, C. Social Media for Scientists Part 3: Win-Win. Scientific American Blog. 10 October 2011.  

    Wilcox, C. Guest Editorial: It’s time to e-Volve. Taking Responsibility for Science Communication in a Digital Age. Biol Bull. 22285-87. (April 2012)  

    The Rules of Social Media.  Fast Company.  8 August 2012. 


    http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

    Source:
    http://feedproxy.google.com/~r/CellTherapyBlog/~3/k7ANTnLXNjc/the-roi-on-pant-wearing-and-other.html

    Read More...

    The ROI on pant-wearing and other social media tips

    Sunday, December 16th, 2012
    Tweet 

    With many things in life, there is a payoff for doing them.  Do the dishes and the kitchen is cleaner, your household is more functional, and hopefully one or more family members notice and appreciate you for it.



    For other things, however,  the people around you have such high expectations you'll do them that you only lose points if you don't but gain very little if you do.  For you, this may be true of the dishes.  Certainly I've always maintained this is true for Valentine's Day.  Get flowers and you simply maintain the relationship's status quo; fail to do anything and you lose big points fast.  


    Similarly, at some point certain things become so ubiquitous that they are expected as a baseline.  This is true of putting on your pants.

    The global head of social media for Ford Motor Company, Scott Monty, once asked, "What's the ROI* of putting your pants on in the morning?".   The truth is that there is very little benefit to putting on your pants other than to avoid the significant cost of not doing so.

    Certainly this is true now of having a website or an email address for your company.  Unlike a couple decades ago, no company gets kudos for having a website or email addresses but it would certainly raise eyebrows of criticism if your company failed to have them.

    Arguably social media participation is not quite there yet but it is, I submit, fast approaching.  Someday in the not-too-distant future you will receive the cringe of shame if your company is not active in the leading social media platforms of the day.  Today - for companies - these are LinkedIn, Twitter, and Facebook.  This will be true irrespective of whether yours is a B2B or B2C company.
    Recently I was invited to write an article for Future Medicine's special issue for the World Stem Cell Report.  I was asked to make the case for why and how participating in social media stood to benefit the scientists, companies, executives, employees, academics, activists, and other stakeholders in the cell therapy industry.  

    The result is "Why the stem cell sector must engage with social media".  What I attempted to succinctly outline are the ways social media primarily benefit one's career and organization or company.


    "I can tell you without the slightest hesitation of conviction – having experienced it myself and seen it repeated countless times – is that active and successful social media engagement translates into:

    • Unparalleled learning: accessing more information relevant to your discipline, specialty and company than you otherwise will. 
    • Enhanced profile: higher profile within your industry, profession, specialty and community. Social media is not the only way to build a profile but it can be very effective.
    • Wider network: more touch points and meaningful relationships with people than you otherwise will accomplish by any other means combined."
    The measurable impacts and benefits are real and certainly include:
    • Traffic: "For companies, increased traffic equals increased opportunity to call readers/viewers to your intended action – interaction, citation, linking, investing, buying or engaging in some other action you solicit. For individual professionals, increased viewers translate into more chances for collaboration, citation, engagement, etc."
    • Collaboration: "There is an intrinsic correlation between one’s profile and the opportunities one has for collaboration. For companies this means finding the right partnerships, joint ventures, strategic alliances, collaborators, employees, management and so on. For individual professionals, this means more and/or better quality invites to speak, write or collaborate in other ways. It also means finding quality grad students, faculty, employees and interns
    • Revenue/IncomeThis is about translating a broader knowledge base and a wider network over which you have some level of influence (if only just that they are listening) into more money for your company, organization and yourself. For companies, this means finding the right partners, investors, customers and so on. For organizations this means finding the right donors, impressing the right grant reviewers and/or recruiting the right rain-maker faculty. For individual professionals this translates into promotions or job offers."

    As I conclude my article I will conclude here:

      "In order to create the kinds of perceptions and solicit the kinds of actions we want from the world around us, we must engage the world around us. The world around us is engaging online. 

      For all kinds of selfish and selfless reasons you, your company or organization and your career will benefit from you engaging there too."

      and this prediction:

      "...in less than the blink it took for the commercial world to accept websites and email, it will seem similarly ridiculous for professionals, academics and companies to operate and succeed without actively using social media."

      ____________


      If this topic is of interest to you, here are some great resources particularly focused on the value of social media to those in life sciences.


      Canaday, M. Is Life Science Social Media Worth It Yet? Three Tenets Behind Its Relevance To Your Business. Comprendia. 6 December 2012. 


      Bersenev A. Scientific blogging as a model for professional networking online. Cellular Therapy and Transplantation. 2010;2(7). 10.3205/ctt-2010-en-000084.01. 


      Bersenev, A. Scientific blogging as a model for professional networking online. 4 August 2010. StemCellAssays.com 


      Bersenev, A. Who’s Who in the Stem Cell Blogosophere.  27 June 2011. StemCellAssays.com 


      Bishop, D.  How to bury your academic writing. Bishop’s Blog. 26 August 2012. 



      Buckler, L. If You’re Breathing, You’re in PR. Cell Therapy Blog. 11 June 2010.  

      Buckler, L. Don’t feel the pain of ignoring social media? Just wait a minute…. CellTherapyBlog.com 22 October 2008.    

      Jewell, T. Survey: How our scientists use social media. AZHealthConnections.com. 12 February 2012. 


      Knoepfer, P. Top ten tips for blogging for scientists. 2 August 2012. IPScell.com   


      Shipman, M. Why Scientists Should Publicize Their Findings – for Purely Selfish Reasons. Scientific America. Blog. 18 June 2012. 
           
      Shipman, M. A gentle introduction to Twitter for the apprehensive academic. Scientific America. Blog.  14 June 2011.  


      Small, G. Time to Tweet. Nature 2011. 479 141 2 November 2011 


      Wilcox, C. Social Media for Scientists Part 1: It’s Our Job. Scientific American Blog. 27 September 2011.  


      Wilcox, C. Social Media for Scientists Part 2: You Do Have time. Scientific American Blog. 29 September 2011.  


      Wilcox, C. Social Media for Scientists Part 3: Win-Win. Scientific American Blog. 10 October 2011.  

      Wilcox, C. Guest Editorial: It’s time to e-Volve. Taking Responsibility for Science Communication in a Digital Age. Biol Bull. 22285-87. (April 2012)  

      The Rules of Social Media.  Fast Company.  8 August 2012. 


      http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

      Source:
      http://feedproxy.google.com/~r/CellTherapyBlog/~3/k7ANTnLXNjc/the-roi-on-pant-wearing-and-other.html

      Read More...

      A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments

      Sunday, December 16th, 2012
      Tweet 


      Further to my recent post, "Six steps to fighting non-compliant cell therapy treatments. The stuff of grey shades, spades, ivory towers and (ahem) balls.", I have crafted a 6-point platform that I propose to submit (with potential edits based on preliminary feedback) to several of the leading  industry and professional organizations for their consideration including ARM, ISCT, ISSCR, FACTAABB  ICMS, and perhaps, in due course, to patient groups, physician groups, disease-specific professional organizations (e.g, cardiology, oncology, neurology, cosmetic, etc).



      I welcome comments and feedback. 


      1. In addition to helping patients distinguish between compliant and non-compliant treatments (and providers) we must do more to help patients distinguish between non-compliant cell therapy treatments (and providers) which are more or less risky. 


      2. Whatever we do in response to this issue should be done with an eye to being practical and helpful to patients in the real-life context of their decision about whether or not to buy a non-complaint cell therapy.


      3. Our response to this issue should be based on a risk-based approach recognizing that not all non-compliance is created equal.  We should create a framework for risk-based analysis (both for us and our audiences) and focus initiatives around those which present the highest risk.


      4. We recognize the problem of non-compliant cell therapies is not just a problem that exists in jurisdictions with little, no, or poor regulation but that is a growing problem even in the most highly regulated jurisdictions meaning the solution cannot be regulated it depends on education and enforcement.


      5. We recognize regulatory agencies cannot enforce non-compliance on their own.  We as an industry need to complement their efforts through our own standards and enforcement.


      6. Stakeholder groups should support the formation of a multi-organizational  initiative to, based on a risk-based assessment, spotlight the categories or signs of highest-risk offenders for use by patients and/or their physicians in identifying  whether or not treatments (and providers) they may be considering fall into the that category associated with the highest level of risk.


      What do you think?

      http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

      Source:
      http://feedproxy.google.com/~r/CellTherapyBlog/~3/wkSMxAV9938/a-proposed-6-step-platform-for-cell.html

      Read More...

      Regenerative Medicine Center, Reviva Lebanon. – Video

      Tuesday, December 11th, 2012


      Regenerative Medicine Center, Reviva Lebanon.
      Our mission is to bring scientific innovation to patients seeking a trace of hope in new medicine therapy through cellular enhancement and medical excellence. We aim to be recognized as an all-in-one leader center in stem cell and regenerative medicine research and applications in the MENA region.From:revivamedicalViews:0 0ratingsTime:05:59More inPeople Blogs

      See the rest here:
      Regenerative Medicine Center, Reviva Lebanon. - Video

      Read More...

      Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF – Video

      Friday, December 7th, 2012


      Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF
      During in-vitro fertilization (IVF), physicians much choose among many embryos to pick the ones that are most likely to produce a successful pregnancy and health child. Shawn Chavez, PhD, a researcher at the Stanford Institute for Stem Cell Biology and Regenerative Medicine, talks about an automated time-lapse recording system that can accurately detect which embryos are healthiest. She discusses new research showing that a parameter called "fragmentation" is important.From:institutesofmedicineViews:3 0ratingsTime:02:05More inEducation

      Originally posted here:
      Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF - Video

      Read More...

      TEDxSalford – Sir Ian Wilmut – From Dolly to Curing Human Disease – Video

      Tuesday, December 4th, 2012


      TEDxSalford - Sir Ian Wilmut - From Dolly to Curing Human Disease
      Sir Ian Wilmut is a world-renowned embryologist and specialist in regenerative medicine. He is best known as the man who led the team that in 1996 first cloned a mammal, a Finn Dorset lamb named "Dolly". Dolly was the first ever clone derived from an adult cell. The research resulting in Dolly #39;s birth stemmed from efforts to genetically engineer sheep and cows in order that their milk would contain human proteins with medicinal properties, such as human antibodies. More recently he was the founding Director of the Centre for Regenerative Medicine in the University of Edinburgh. The Mission of this rapidly expanding Centre is to develop new treatments for human disease through innovative research with stem cells. The new Centre covers the full spectrum of research -- from basic mechanisms of stem cell biology, to clinical trials with stem cells and their derivatives. The aim of his own research is to be able to produce human cells for use in research and in future for treatment of diseases, such as motor Neuron Disease. In his talk he will describe the way in which the cloning research has provided revolutionary new opportunities in regenerative medicine. Credits: Camerawork: Nathan Rae Team - nathanrae.co.uk Post production: Elliott Wragg - twitter.com Audio restoration : Jorge Polvorinos - jorgepolvorinos.wordpress.com Heat of IT and Design Vlad Victor Jiman - twitter.comFrom:TEDxTalksViews:41 4ratingsTime:19:27More inNonprofits Activism

      The rest is here:
      TEDxSalford - Sir Ian Wilmut - From Dolly to Curing Human Disease - Video

      Read More...

      World Stem Cell Summit – Terzic – Video

      Tuesday, December 4th, 2012


      World Stem Cell Summit - Terzic
      The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers. In this video, Dr. Andre Terzic, director of the Mayo Clinic Center for Regenerative Medicine addresses the importance of the summit and the emerging field of regenerative medicine.From:mayoclinicViews:6 0ratingsTime:05:34More inScience Technology

      See the original post here:
      World Stem Cell Summit - Terzic - Video

      Read More...

      The World Stem Cell Summit – Dr. Yaszemski – Video

      Tuesday, December 4th, 2012


      The World Stem Cell Summit - Dr. Yaszemski
      The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers, including leaders from Mayo Clinic #39;s Center for Regenerative Medicine. Among them is Mayo Clinic Dr. Michael Yaszemski. In this video he talks about the summit, the emerging field of regenerative medicine and his unique military perspective.From:mayoclinicViews:5 0ratingsTime:04:16More inScience Technology

      Read the rest here:
      The World Stem Cell Summit - Dr. Yaszemski - Video

      Read More...

      World Stem Cell Summit – Windebank – Video

      Tuesday, December 4th, 2012


      World Stem Cell Summit - Windebank
      The World Stem Cell Summit, December 3-5 in West Palm Beach, Fla. unites internationally renowned scientists, clinicians, students, policymakers, regulators, patient advocates, and philanthropists to share knowledge and advance collaborations in the stem cell and regenerative medicine community. The meeting includes in-depth programming and more than 150 renowned international speakers, including leaders from Mayo Clinic #39;s Center for Regenerative Medicine. In this video, Dr. Anthony Windebank talks about the emerging field of regenerative medicine.From:mayoclinicViews:8 0ratingsTime:03:39More inScience Technology

      Read more here:
      World Stem Cell Summit - Windebank - Video

      Read More...

      Page 48«..1020..47484950..60..»


      2025 © StemCell Therapy is proudly powered by WordPress
      Entries (RSS) Comments (RSS) | Violinesth by Patrick